Approval · Notice of Compliance 3517 · 2003
ZANTAC: Notice of Compliance 3517
Issued April 14, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3517
- Date
- April 14, 2003
- Company
- Pfizer Canada Inc., Consumer Healthcare DivisionMarkham, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Admin
- Reason
- Product name change from zantac 75
- Therapeutic class
- Histamine H2-receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZANTAC | 02230287 | Cancelled Post Market |
Medicinal ingredients
- RANITIDINE HCL 75 MG per TAB